Agilent Launches High-Capacity S540MD Digital Pathology Scanner in US

Agilent Technologies (NYSE: A) has launched a high-capacity digital slide scanner in the United States, targeting clinical laboratories managing rising sample volumes and preparing for automated, artificial intelligence-driven diagnostic workflows. First reported by Yahoo Finance (https://finance.yahoo.com/healthcare/articles/agilent-wants-pathology-labs-digital-195217186.html), the Agilent S540MD carries U.S. Food and Drug Administration clearance and holds up to 540 glass slides simultaneously.

The device is engineered for high-throughput environments, featuring continuous loading capabilities that allow laboratory technicians to refill slide trays during active operation. The unit accepts standard diagnostic racks and integrates automated tissue detection and scanning modes into existing laboratory infrastructure. Majken Nielsen, head of Agilent's Clinical Diagnostics Division, positioned the scanner as a mechanism to connect slide digitization directly with the company's established staining workflows.

The U.S. commercial rollout on Sept. 4 follows an initial release in select European markets in January. The scanner is currently sold across the U.S. alongside the United Kingdom, Germany, France, and other European countries. The underlying hardware is a rebadged Hamamatsu NanoZoomer S540MD, meaning Agilent's commercial advantage relies on integration with its existing diagnostic workflows and pathology software rather than proprietary scanner mechanics. Agilent has not disclosed pricing, unit shipment targets, or direct revenue forecasts for the hardware.

The product rollout follows quarterly earnings reported on Aug. 26 for the period ended July 31. Agilent posted third-quarter revenue of $1.88 billion, up 8.1% year over year, while non-GAAP earnings per share rose 18%. Chief Executive Officer Padraig McDonnell attributed the growth to improving end markets, stronger regional demand, and customer adoption of new products. Following the results, Agilent raised its full-year non-GAAP earnings guidance to between $6.18 and $6.21 per share.

The financial performance included non-operational gains, with tariff refunds contributing $0.06 to third-quarter non-GAAP earnings per share and factoring into the updated full-year forecast. Management's fourth-quarter guidance projects core revenue growth between 5.2% and 6.2%—a moderation from 7.3% core growth in the third quarter—and assumes no further tariff refunds.

Institutional holding data shows 62 hedge funds held Agilent shares at quarter end compared to 63 in the preceding quarter, while short interest stood at 2.29% of the float. As of Sept. 18, the stock traded at 22.62 times forward earnings. Agilent's long-term digital pathology gains will depend on whether high-volume clinical labs adopt the S540MD alongside its staining platforms as fourth-quarter core growth slows.